Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. Howeve

Trial Details

NCT ID
NCT07094048
Phase
PHASE4
Sponsor
CHU de Quebec-Universite Laval
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Target trough IgG level of 8-10 g/L
  • Target trough IgG level 4-6 g/L
  • No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
Locations (sample)
  • Québec, Quebec, Canada|46.81228,-71.21454

Key Eligibility Criteria

  • Multiple myeloma patient:
  • ≥ 18 years old
  • ≥ 1 prior lines of therapy
  • Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →